PCVX insider filing: Elvia Cowan reports RSU and option grants on 08/29/2025
Rhea-AI Filing Summary
Vaxcyte, Inc. (PCVX) Form 4: Elvia Cowan, SVP Finance, reported equity awards and purchases. On 08/29/2025 she was granted 2,810 restricted stock units (RSUs) that convert to common shares at vesting and a stock option covering 9,743 shares with an exercise price of $30.79 that vests monthly beginning 09/29/2025 and expires 08/29/2035. Following the reported RSU grant the filing shows she beneficially owns 27,205 shares, which includes 289 shares acquired under the Employee Stock Purchase Plan on 05/16/2025. All reported holdings are direct.
Positive
- Equity awards align executive incentives via RSUs and options that vest over multiple years
- Clear disclosure of vesting schedules and exercise price enhances transparency for investors
Negative
- Grants create potential dilution if and when options are exercised and RSUs vest
- No sale activity reported, so there is no liquidity or diversification by the reporting person
Insights
TL;DR: Routine executive compensation grants; not an immediate liquidity event and likely intended for retention and alignment with shareholders.
The Form 4 discloses standard equity-based compensation: RSUs with multi-year vesting and an option grant with a 10-year term and monthly vesting after initial cliff. These are typical instruments to align a senior finance officer’s incentives with long-term shareholder value. The exercise price of $30.79 sets the strike for potential future purchases but does not indicate any exercised transactions. The incremental dilution from these awards is modest relative to typical public-company share counts, and no sales or transfers reducing ownership were reported.
TL;DR: Disclosure is clear and complete for the reported grants; vesting schedules and direct ownership are specified.
The filing provides required detail: grant types, vesting cadence, exercise price, and post-transaction beneficial ownership. RSU vesting (25% then 12.5% semiannually) and option vesting (1/48 monthly after a one-month initial increment) are explicitly stated, supporting transparency on when shares may be delivered. No indication of a 10b5-1 plan or sales; the form appears consistent with governance best practices for executive award disclosures.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 2,810 | $0.00 | -- |
| Grant/Award | Stock Option (right to buy) | 9,743 | $0.00 | -- |
Footnotes (1)
- Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on March 7, 2026 and 12.5% of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Includes 289 shares acquired under the Issuer's Employee Stock Purchase Plan on May 16, 2025. 1/48 of shares subject to the option vest on September 29, 2025, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
